Skip to main content

Or 34,00 After 66% tax deduction

I make a monthly donation I make an IFI donation
Research, science & health

Coffee to treat a form of dyskinesia

Published on: 19/04/2022 Reading time: 1 min
image
Retour à la recherche

Dyskinesias are rare diseases characterised by sudden, involuntary movements that can affect the whole body. Two years ago, the team of Prof. Flamand-Roze and Dr. Méneret at the Paris Brain Institute and the neurology department of the Pitié-Salpêtrière Hospital AP-HP published the case of a child suffering from a form of the disease linked to the ADCY5 gene. This young patient was able to return to a normal life thanks to coffee. In a collaborative study, the same team has just confirmed this result by collating data from 30 patients worldwide who were also treated with coffee. 87% of them saw their symptoms improve significantly. This result could, according to the researchers, be explained by the fixation of coffee in the striatum, a deep region of the brain that is crucial for the control of movement. Their discovery, published in the journal Movement Disorders, could pave the way for the development of new treatments for movement disorders.

Dyskinesias are a group of rare disorders characterised by sudden, involuntary movements that can affect the whole body. One of the causes of this condition is a mutation in the ADCY5 gene, which starts mainly in childhood. These abnormal movements are often exacerbated in the form of paroxysmal movement disorders that can occur during the day, but also at night. Despite numerous explorations of the potential benefits of drug treatments, until recently no treatment has been confirmed to be effective in this condition.

Two years ago, a long-standing study by Prof. Emmanuel Flamand-Roze and Dr. Aurélie Méneret highlighted the benefit of caffeine on the symptoms of a child suffering from dyskinesia associated with the ADCY5 gene mutation. In order to confirm these results, the team from the Paris Brain Institute, the neurology department of the Pitié-Salpêtrière AP-HP hospital and Inserm conducted a retrospective study on a worldwide scale. The researchers were able to collect data from 30 patients affected by this rare condition who had consumed or were still consuming coffee for their dyskinesia.

Their results show that, in addition to a good tolerance of caffeine intake, including in children, 87% of patients reported a clear improvement in their motor symptoms. Coffee consumption not only reduced the frequency and duration of paroxysmal movement disorders, but also reduced their baseline movement disorders, as well as other symptoms such as gait, attention and concentration disorders, certain types of pain or hypotonia, with a notable improvement in the patients’ quality of life. This retrospective study thus confirms the potential of caffeine as a first-line treatment in this form of dyskinesia.

The efficacy of coffee can be explained by the fact that caffeine binds to adenosine receptors that modify the function of the dysfonctional protein (ADCY5). The latter is strongly located in the striatum of the brain, which is involved in motor control. Researchers and clinicians at the Paris Brain Institute are currently exploring the interest of the cyclic adenosine monophosphate (cAMP) pathway as a therapeutic target in this disease and more widely in pathologies associated with hyperkinetic movements.

Sources

https://pubmed.ncbi.nlm.nih.gov/35384065/
Méneret A, Mohammad SS, Cif L, Doummar D, DeGusmao C, Anheim M, Barth M, Damier P, Demonceau N, Friedman J, Gallea C, Gras D, Gurgel-Giannetti J, Innes EA, Necpál J, Riant F, Sagnes S, Sarret C, Seliverstov Y, Paramanandam V, Shetty K, Tranchant C, Doulazmi M, Vidailhet M, Pringsheim T, Roze E.Mov Disord. 2022 Apr 5.

Our news on the subject

Stimuler les mitochondries pour doper la mémoire à long terme
Stimulating Mitochondria to Boost Long-Term Memory
An international team led by Jaime de Juan-Sanz at the Paris Brain Institute has shown that slightly increasing the metabolic capacity of neurons can enhance long-term memory in both fruit flies and mice. The study, published in Nature Metabolism...
02.24.2026 Research, science & health
Traitements anti-Alzheimer
Anti-Alzheimer Treatments: A Long-Term Beneficial Effect on Symptoms
There is currently no cure for Alzheimer's disease. The treatments available in France—which are not reimbursed—are known as symptomatic treatments, meaning that they act on the consequences of the disease rather than its underlying cause. In 2018...
02.19.2026 Research, science & health
État de mal épileptique
Status Epilepticus: New Insights Gained from National Health Data
The most severe form of epilepsy, status epilepticus is a high-risk neurological emergency. Yet its epidemiology remains poorly understood, particularly in France. By analyzing data from the French National Health Insurance system, compiled within...
02.19.2026 Research, science & health
Sclérose en plaques : identification d’une nouvelle molécule favorisant la remyélinisation
Multiple Sclerosis: Identification of a Molecule that Promotes Repair of the Nervous System
A molecule previously studied in the context of sleep disorders and attention deficit hyperactivity disorder (ADHD) is now, for the first time, revealing its potential in experimental models of multiple sclerosis (MS): it protects neurons and...
01.27.2026 Research, science & health
VignetteActu WBHF 2026
World Brain Health Forum 2026
More than one in three people will experience a brain disorder at some point in their lives. This reality, identified by the World Health Organization as a major public health priority, calls for unprecedented international mobilization. It is...
01.12.2026 Events
Une nouvelle approche pour évaluer les patients en état de conscience altérée
A New Approach to Assessing Patients with Disorders of Consciousness
In intensive care units, some patients who appear unconscious occupy a gray zone in their relationship to the world. To better diagnose them and predict their recovery potential, Dragana Manasova, Jacobo Sitt, and their colleagues have developed an...
01.08.2026 Research, science & health
See all our news